CoJourney
Private Company
Funding information not available
Overview
CoJourney is a specialized CDMO focused on accelerating the development and manufacturing of advanced cell and gene therapies. Founded in 2019 and headquartered in Boston with significant operations in Horsham, PA and Hangzhou, China, the company leverages its proprietary Zero Chrom® plasmid platform and viral vector expertise to offer high-yield, cost-effective manufacturing solutions. With over 100 clients served and a recent $30 million financing round, CoJourney is positioned as a key enabler for biotechs navigating complex CMC and regulatory pathways.
Technology Platform
Proprietary Zero Chrom® plasmid manufacturing platform for high-purity, low-cost production; scalable viral vector (AAV, Lenti), sgRNA, and exosome manufacturing platforms.
Opportunities
Risk Factors
Competitive Landscape
CoJourney competes in the fragmented but growing advanced therapies CDMO space against giants like Lonza, Catalent, and Thermo Fisher, as well as specialized peers like Oxford Biomedica, Genezen, and Vigene Biosciences. Its differentiation hinges on its proprietary, cost-focused plasmid platform and integrated service offering for key gene therapy raw materials.